vs
FIRST INDUSTRIAL REALTY TRUST INC（FR）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
FIRST INDUSTRIAL REALTY TRUST INC的季度营收约是再鼎医药的1.5倍（$194.8M vs $127.1M），再鼎医药同比增速更快（17.1% vs 10.0%），过去两年再鼎医药的营收复合增速更高（20.8% vs 8.9%）
该企业是一家房地产投资信托机构，主要投资华盛顿大都会区郊区的工业地产与商务园区类资产，拥有成熟的不动产投资运营经验，于2017年被政府物业收入信托正式收购。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
FR vs ZLAB — 直观对比
营收规模更大
FR
是对方的1.5倍
$127.1M
营收增速更快
ZLAB
高出7.1%
10.0%
两年增速更快
ZLAB
近两年复合增速
8.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $194.8M | $127.1M |
| 净利润 | $147.9M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 75.9% | — |
| 营收同比 | 10.0% | 17.1% |
| 净利润同比 | 179.7% | — |
| 每股收益（稀释后） | $1.08 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FRZLAB
| Q1 26 | $194.8M | — | ||
| Q4 25 | $188.4M | $127.1M | ||
| Q3 25 | $181.4M | $115.4M | ||
| Q2 25 | $180.2M | $109.1M | ||
| Q1 25 | $177.1M | $105.7M | ||
| Q4 24 | $175.6M | $108.5M | ||
| Q3 24 | $167.6M | $101.8M | ||
| Q2 24 | $164.1M | $100.1M |
净利润FRZLAB
| Q1 26 | $147.9M | — | ||
| Q4 25 | $78.8M | — | ||
| Q3 25 | $65.3M | $-36.0M | ||
| Q2 25 | $55.2M | $-40.7M | ||
| Q1 25 | $48.1M | $-48.4M | ||
| Q4 24 | $68.4M | — | ||
| Q3 24 | $99.4M | $-41.7M | ||
| Q2 24 | $51.3M | $-80.3M |
毛利率FRZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率FRZLAB
| Q1 26 | — | — | ||
| Q4 25 | 34.6% | -54.6% | ||
| Q3 25 | 37.0% | -42.3% | ||
| Q2 25 | 31.7% | -50.3% | ||
| Q1 25 | 31.2% | -53.3% | ||
| Q4 24 | 40.1% | -62.6% | ||
| Q3 24 | 62.6% | -66.6% | ||
| Q2 24 | 31.8% | -76.0% |
净利率FRZLAB
| Q1 26 | 75.9% | — | ||
| Q4 25 | 41.8% | — | ||
| Q3 25 | 36.0% | -31.2% | ||
| Q2 25 | 30.6% | -37.3% | ||
| Q1 25 | 27.2% | -45.8% | ||
| Q4 24 | 39.0% | — | ||
| Q3 24 | 59.3% | -40.9% | ||
| Q2 24 | 31.3% | -80.2% |
每股收益（稀释后）FRZLAB
| Q1 26 | $1.08 | — | ||
| Q4 25 | $0.60 | $-0.05 | ||
| Q3 25 | $0.49 | $-0.03 | ||
| Q2 25 | $0.42 | $-0.04 | ||
| Q1 25 | $0.36 | $-0.04 | ||
| Q4 24 | $0.51 | $-0.09 | ||
| Q3 24 | $0.75 | $-0.04 | ||
| Q2 24 | $0.39 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $715.5M |
| 总资产 | $5.8B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FRZLAB
| Q1 26 | — | — | ||
| Q4 25 | $78.0M | $689.6M | ||
| Q3 25 | $33.5M | $717.2M | ||
| Q2 25 | $34.9M | $732.2M | ||
| Q1 25 | $35.7M | $757.3M | ||
| Q4 24 | $44.5M | $779.7M | ||
| Q3 24 | $47.1M | $616.1M | ||
| Q2 24 | $38.5M | $630.0M |
股东权益FRZLAB
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.7B | $715.5M | ||
| Q3 25 | $2.7B | $759.9M | ||
| Q2 25 | $2.6B | $791.7M | ||
| Q1 25 | $2.7B | $810.8M | ||
| Q4 24 | $2.7B | $840.9M | ||
| Q3 24 | $2.6B | $667.7M | ||
| Q2 24 | $2.6B | $704.2M |
总资产FRZLAB
| Q1 26 | $5.8B | — | ||
| Q4 25 | $5.7B | $1.2B | ||
| Q3 25 | $5.5B | $1.2B | ||
| Q2 25 | $5.5B | $1.2B | ||
| Q1 25 | $5.4B | $1.2B | ||
| Q4 24 | $5.3B | $1.2B | ||
| Q3 24 | $5.2B | $985.3M | ||
| Q2 24 | $5.2B | $987.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流FRZLAB
| Q1 26 | — | — | ||
| Q4 25 | $461.3M | $-26.0M | ||
| Q3 25 | $124.6M | $-32.0M | ||
| Q2 25 | $126.1M | $-31.0M | ||
| Q1 25 | $88.6M | $-61.7M | ||
| Q4 24 | $352.5M | $-55.8M | ||
| Q3 24 | $105.5M | $-26.8M | ||
| Q2 24 | $107.7M | $-42.2M |
自由现金流FRZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M |
自由现金流率FRZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% |
资本支出强度FRZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% |
现金转化率FRZLAB
| Q1 26 | — | — | ||
| Q4 25 | 5.85× | — | ||
| Q3 25 | 1.91× | — | ||
| Q2 25 | 2.28× | — | ||
| Q1 25 | 1.84× | — | ||
| Q4 24 | 5.15× | — | ||
| Q3 24 | 1.06× | — | ||
| Q2 24 | 2.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FR
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
